

Search

EN

Back

Giant Biogene Wins China Approval for First-of-its-Kind Aesthetic Implant

Back

Stock NewsThemesGiant Biogene Wins China Approval for First-of-its-Kind Aesthetic Implant

Giant Biogene Wins China Approval for First-of-its-Kind Aesthetic Implant

Edgen Stock·Jan 15 2026, 10:02

Share to

Share to

Copy link

GIANT BIOGENE+2.27%

source:

[1] Giant Biogene (02367)'s subsidiary obtains a registration certificate for a product

Recommend

Celanese Q4 Earnings Plunge 54%, Missing EstimatesFeb 17 2026, 23:34 RB Global Beats Q4 Estimates With $1.11 EPSFeb 17 2026, 23:33 Mercury General Crushes Q4 Forecasts With $3.66 EPSFeb 17 2026, 23:32

Hot News

Similarweb Swings to Profit, Beating Q4 EstimatesFeb 17 2026, 23:58

Hormel Sells Turkey Business, Reaffirms 2026 GuidanceFeb 17 2026, 23:57

Axcelis Q4 Profit Crushes Estimates by 33%Feb 17 2026, 23:35

Halozyme Reports Unexpected Q4 Loss of $0.24 Per ShareFeb 17 2026, 23:35

Features

AI Copilot for Stock & Crypto

Price Prediction

Fundraise Tracker

Crypto Comparison

Resources

Market

Terms of Use Privacy Policy Sitemap

© 2026 Finture Development Limited. All rights reserved